Polymyxin B-Resistant Acinetobacter baumannii Clinical Isolate Susceptible to Recombinant BPI 21 and Cecropin P1
Open Access
- 1 March 2001
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 45 (3) , 994-995
- https://doi.org/10.1128/aac.45.3.994-995.2001
Abstract
Many strains of Acinetobacter baumannii have become resistant to a variety of clinically available antibacterial agents by both intrinsic and extrinsic mechanisms ([4][1], [15][2]). Several investigators have documented multidrug-resistant A. baumannii causing nosocomial infections and haveKeywords
This publication has 23 references indexed in Scilit:
- AcinetobacterSeminars in Respiratory and Critical Care Medicine, 2000
- In Vitro Activities of Nontraditional Antimicrobials against Multiresistant Acinetobacter baumannii Strains Isolated in an Intensive Care Unit OutbreakAntimicrobial Agents and Chemotherapy, 2000
- Peptide Antibiotics1999
- Intravenous Colistin as Therapy for Nosocomial Infections Caused by Multidrug‐Resistant Pseudomonas aeruginosa and Acinetobacter baumanniiClinical Infectious Diseases, 1999
- Successful Treatment of Ventriculitis Due to Carbapenem‐ResistantAcinetobacter baumanniiwith Intraventricular Colistin Sulfomethate SodiumClinical Infectious Diseases, 1999
- Bactericidal/Permeability-Increasing Protein (rBPI21) in Patients with Hemorrhage Due to TraumaThe Journal of Trauma: Injury, Infection, and Critical Care, 1999
- Preliminary evaluation of recombinant amino-terminal fragment of human bactericidal/permeability-increasing protein in children with severe meningococcal sepsisThe Lancet, 1997
- Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactamThe Lancet, 1994
- Infections Caused by Imipenem-Resistant Acinetobacter calcoaceticus Biotype anitratusThe Journal of Infectious Diseases, 1993